Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
A legfontosabb adatok
- Ki végzi
- Novartis Pharmaceuticals
- Hol
- Dél-Korea, Japán, Kína és Tajvan10 helyszín, 4 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 36 fő vett részt
- Kezdés
- 2020. nov. 4.
- Befejezés
- 2024. dec. 6.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- eltrombopag
- rabbit anti-thymocyte globulin (r-ATG)
- cyclosporine A (CsA)
- A regiszteradat frissítve
- 2026. január 13.
Ki vehet részt
- Életkor
- 6 év – 100 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Written study informed consent and (where applicable) assent from the subject, parent, or guardian must be obtained prior to participation in the study
- Subjects of East Asian ethnicity aged ≥ 6 years old at the time of written informed consent and assent form (if applicable)
- SAA characterized by:
- Bone marrow cellularity < 25%, or 25-50% with < 30% residual hematopoietic cells and pancytopenia, with at least two of the following parameters in peripheral blood:
- Absolute neutrophil count < 0.5×109/L
- Platelet count < 20×109/L
- Absolute reticulocyte count < 20×109/L
- HSCT not suitable or available as a treatment option (determined as per local practices or national guidelines), or has been refused by subject
Ki nem vehet részt
- Prior IST with any ATG/ALG , alemtuzumab, high dose cyclophosphamide (≥ 45 mg/kg/day), CsA within 6 months, or prior thrombopoietin receptor agonists
- Prior and/or active medical history of:
- Any concomitant malignancies that have not fully recovered from treatment or have not been disease-free for 5 years
- Past medical history of thromboembolism within 6 months, and/or prior or current antiphospholipid antibody syndrome (APS)
- Presence of clinically active uncontrolled significant (of such severity that it would preclude the subject's ability to consent, be compliant with study procedures, tolerate protocol therapy) infection, including bacterial, fungal, mycobacterial, parasitic or viral infection, or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol
- Known underlying congenital/inherited bone marrow failure or aplastic anemia (e.g.,such as but not limited to Fanconi anemia, congenital dyskeratosis, congenital amegakaryocytic thrombocytopenia, or Shwachman-Diamond Syndrome)
- Myelodysplastic syndrome (MDS)
- Any severe and/or uncontrolled medical conditions which could cause unacceptable safety risks or compromise compliance with the protocol, such as:
- Known hepatocellular disease (e.g. active hepatitis or cirrhosis)
- Impairment of gastrointestinal (GI) function or gastrointestinal disease that may significantly alter the absorption of study treatment (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
- Active skin, mucosa, ocular or GI disorders of Grade > 1
- Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening. A positive serology for Hepatitis B (HB) is considered as a positive test for HBsAg. In addition, if serology is negative for HBsAg but hepatitis B core antibody (HBcAb) is positive (regardless of hepatitis B surface antibody (HBsAb) status), a hepatitis B virus (HBV) DNA test will be performed and if positive the patient will be excluded
- Cardiac disorder (subjects with congestive heart disease of New York Heart Association (NYHA) functional classification Grade II/III/IV (for pediatric subjects, refer to the Grade II/III/IV of Modified ross heart failure classification for Children) should not be enrolled; subjects with NYHA Grade II due to cardiac disorder should not be enrolled but those with NYHA Grade II due to aplastic anemia (AA) may be enrolled.), arrhythmia with a risk of thrombosis (e.g. atrial fibrillation), pulmonary hypertension, or uncontrolled hypertension (>180/100 mmHg)
- Symptomatic paroxysmal nocturnal hemoglobinuria (PNH) and/or PNH clones >50% of polymorphonuclear neutrophil (PMN) or RBC at time of enrollment
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN)
- Creatinine ≥ 2.5×local ULN
- Eastern Cooperative Oncology Group (ECOG) performance status (age ≥ 16 years) >2, or Lansky performance status (age < 16 years) <50
- Any cytogenetic abnormalities on karyotyping or FISH within 30 days of study enrollment (an evaluable karyotyping with at least 10 metaphases is mandatory for eligibility)
- Other known or suspected underlying primary immunodeficiency
Hol van ez a vizsgálat?
4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with severe aplastic anemia (SAA).
A vizsgálat csoportja
- eltrombopagA vizsgált kezelés
Participants received eltrombopag in combination with r-ATG and CsA. * Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count * r-ATG was administered intravenously at a dose of 2.5 to 3.5 mg/kg/day on Days 1-5 * CsA was administered orally every 12 h at a starting dose of 3-6 mg/kg/day
Kezelés: eltrombopag, rabbit anti-thymocyte globulin (r-ATG) és cyclosporine A (CsA)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine A (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS)
- A regiszteradat frissítve
- 2026. január 13.